New Clinical Trial Shows Why Vitamin D Matters in Covid-19
If restoring proper vitamin D3 levels supports viral clearance, does that mean its deficiency fuels the spread of Covid-19?
In August, a randomized clinical trial first showed that oral calcifediol (also called vitamin D3) reduced the odds of intensive care unit (ICU) admission from 50% (13 out of 26) to 2% (one out of 50) among Covid-19 patients. “Although this was a small trial, the ICU results are so dramatic that they are statistically highly significant,” stated a featured letter in The BMJ.
This month, another Covid-19 clinical trial on vitamin D3 from India was published in the Postgraduate Medical Journal of the British Medical Journal, titled “Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study).” And this study shows why healthy vitamin D status matters in Covid-19.
What the new clinical trial did and found
The trial randomly allocated asymptomatic or mild Covid-19 participants to the treatment (vitamin D3 liquid) or placebo (distilled water) groups. The treatment group had 16 participants, and the control group had 24. Notably, all participants were vitamin D3 deficient (<20…
